期刊
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
卷 22, 期 1, 页码 75-82出版社
ELSEVIER
DOI: 10.1016/S1773-2247(12)50007-9
关键词
RNAi; Carbosilane dendrimers; Dendrimers; Non-viral vectors; HIV infection
资金
- MNT-ERA NET transnational call
- COST Action [TD0802]
- Fondo de Investigacion Sanitaria [PI09/02029, PI080222, PI081495]
- Fundacion para la Investigacion y la Prevention del SIDA en Espana (FIPSE) [240800/09]
- EuroEraNet DENPEPTHIV [PS09/02669]
- CIBER-BBN del Instituto de Salud Carlos III
- Programa de Investigacion de la Consejeria de Sanidad de la Comunidad de Madrid
- [RedRIS RD06-0006-0035]
- [DENANORA]
Despite the enormous possibilities of RNAi, there still exist many problems that need to be addressed. Obstacles in delivery, target cell transfection, stabilityldegradation, transient activity, secondary effects, toxicity caused by the delivery vector, and resistance all hinder the path of carrying out in vivo experiments with RNAi and further developing RNAi as a new therapy for clinical use Notwithstanding, the majority of research that uses RNAi depends on a delivery vector of some kind. This review offers a brief overview of the current status of carbosilane dendrimers as siRNA delivery vectors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据